Clinical Trial Update: L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of L-DOS47 plus doxorubicin in advanced pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• L-DOS47

Snippet

Sponsor: Helix BioPharma Corporation | Conditions: Pancreas Cancer | Phase 1, Phase 2 | Status: TERMINATED